glp-1 cancer prevention The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and | Cancer and Metastasis Reviews GLP-1 drugs and colorectal cancer

2) Under conditions of sustained systemic inflammation (as seen in PEM), high levels of circulating cytokines may degrade tight junction proteins (e.g., claudin-5 and occludin), leading to BBB disruption and increased paracellular permeability

Acknowledgements The authors express their gratitude to Richard Miles (Institut du Cerveau et de la Moelle Epinire, Paris, France) and Johan Pallud (Neurosurgery Department, Paris Descartes University, Sainte-Anne Hospital, Paris, France) for reading the manuscript

Analogous to the well-documented ability of GLP-1R agonists to reduce appetite and food intake, there is increasing data on their ability to reduce ethanol intake in patients with AUD 7,8

10.1016/j.bmc.2019.03.007 159